If you were unable to join me yesterday, a replay of the Sharecafe webinar will be available on AdAlta Limited website shortly.

The NSW Government is building a Viral Vector Manufacturing Facility (VVMF), the 1st of its kind in Australia & establishing a ‘for-profit’ organisation to own and operate the VVMF. They are hiring 2 key personnel to fill the positions of #CFO & #CEO. View info⬇️for details!

Excited to be taking AD-214 back to the clinic earlier than anticipated. Find out why at our webinar on Wednesday 3 May 1030 AEST

$1AD Healthcare stocks maintain clinical momentum in 2023’s March quarter. Proactive Australia spotlights AdAlta as one of the biotechs delivering dynamic solutions that combat modern healthcare woes. tinyurl.com/2qrma8mv @AdAltaCEO #1AD

Don’t miss out on the AdAlta Limited Entitlement Offer, which is closing on Monday at 5pm AEST. If you are an eligible shareholder and yet to participate, we would like to remind you to consider taking up your rights. More info bit.ly/3IpHjSC $1AD #ASX #fibrosis #oncology

Thank you to AdAlta Limited shareholders who have given our capital raise a flying start: proactiveinvestors.com.au/companies/news…

Great weekend at #ASCO23. Humbling to see the amazing minds and science being deployed to treat cancer. Exciting to gain new insights to ⁦AdAlta Limited⁩ ‘s potential to contribute with our #ibody platform and i-CAR-T programs

Four days of high octane partnering at #BIO23 in Boston. Material progress on ⁦⁦AdAlta Limited⁩ ‘s three partnering streams: out-licensing AD-214; partnering the i-body platform; and evaluating complimentary technologies and products. 48 meetings done. Best BIO yet.

Hard to over-estimate the significance of this data for AdAlta Limited : AD-214 could be effective at clinically viable dosing regimens. De-risks clinical trials, enhances partnering

Thanks those who saw AdAlta Limited (ASX: 1AD) CEO Tim Oldham present at The Capital Network's Emerging ASX Gems. Watch AdAlta at 17:40sec for an update on pipeline & the partnering opps flowing from data linking AD-214 preclinical animal studies & Phase I human results supporting efficacy

A quick synopsis of the important data AdAlta Limited released today

Sharing the ⁦AdAlta Limited⁩ story at ⁦@PeakAsset⁩ Microcap Conference today: new AD-214 data; partnering progress; blue sky transaction upside; oversubscribed shortfall placement

Fibrosis is a serious condition impacting millions globally. At AdAlta Limited we’re working on new therapeutics to treat it. As part of Pulmonary Fibrosis Awareness Month, we look at fibrosis, its impacts & how we’re working to treat it. Read article: bit.ly/3ORUMVu $1AD

It's Pulmonary Fibrosis Awareness Month. As proud sponsors of double lung transplant recipient, Bill Van Nierop, AdAlta Limited encourages you to support Bill's Long Kayak for Lungs 2, to raise $ for research & increase awareness of lung disease. dailymotion.com/video/x8njpjl

Possibly our most important data this year so far …

“It’s some of the coolest technology floating around in biotech today”.The Market Bull - Daily Stock News & Tim Oldham discuss AdAlta’s exciting progress & partnering opps for our i-body drug discovery platform; lead drug AD-214 for #fibrotic diseases & CAR-T cell therapy for cancer tumours.$1AD

AdAlta Limited is pleased to invite shareholders/potential investors to a series of upcoming briefings at ASA | Australian Shareholders' Association Investor Summit 2023 and in person. #1AD CEO & MD Dr Tim Oldham will discuss #AD214 and partnering. Register: tinyurl.com/muuce4bx $1AD #IPF

Stockhead has released a special report on the countdown to AdAlta (ASX:1AD) trial results as biotech advances partner discussions. Read more here: buff.ly/3UxhA1k @stockheadAU #1AD #Biotech #ASX

Join AdAlta’s CEO and Managing Director, Tim Oldham as he sits on an expert panel at the 2nd Australia Biologics Festival (20 Feb 2024) | imapac.com/events/austral… #1AD IMAPAC #Biologics

AdAlta (ASX:1AD) is presenting at Peak Asset Management's Biotech Showcase on 21 August in Melbourne. Hear about our latest developments & investment insights from top advisors. Space is limited, so register now for FREE! peak.contact